SB
BMRN icon

Suntrust Banks’s BioMarin Pharmaceuticals BMRN Stock Holding History

Suntrust Banks’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$716K Sell
10,624
-3,527
-25% -$272K ﹤0.01% 840
2019
Q2 		$1.21M Sell
14,151
-1,685
-11% -$144K 0.01% 718
2019
Q1 		$1.41M Buy
15,836
+1,123
+8% +$104K 0.01% 674
2018
Q4 		$1.25M Buy
14,713
+806
+6% +$76.7K 0.01% 654
2018
Q3 		$1.35M Buy
13,907
+3,800
+38% +$379K 0.01% 667
2018
Q2 		$953K Buy
10,107
+1,724
+21% +$151K 0.01% 751
2018
Q1 		$680K Buy
8,383
+3,182
+61% +$273K ﹤0.01% 812
2017
Q4 		$464K Sell
5,201
-22
-0.4% -$1.91K ﹤0.01% 889
2017
Q3 		$486K Buy
5,223
+1,500
+40% +$133K ﹤0.01% 886
2017
Q2 		$338K Buy
3,723
+868
+30% +$79K ﹤0.01% 999
2017
Q1 		$251K Buy
+2,855
New +$254K ﹤0.01% 1100
2016
Q3 		– Sell
-7,153
Closed -$555K – 1540
2016
Q2 		$555K Sell
7,153
-2,111
-23% -$179K ﹤0.01% 918
2016
Q1 		$763K Buy
9,264
+94
+1% +$7.65K ﹤0.01% 785
2015
Q4 		$958K Buy
+9,170
New +$958K 0.01% 701
2015
Q1 		– Sell
-3,138
Closed -$283K – 1226
2014
Q4 		$283K Sell
3,138
-16,471
-84% -$1.37M ﹤0.01% 1009
2014
Q3 		$1.41M Sell
19,609
-1,770
-8% -$116K 0.01% 532
2014
Q2 		$1.33M Buy
21,379
+4,474
+26% +$270K 0.01% 588
2014
Q1 		$1.15M Sell
16,905
-493
-3% -$36.3K ﹤0.01% 896
2013
Q4 		$1.22M Sell
17,398
-2,523
-13% -$171K ﹤0.01% 839
2013
Q3 		$1.44M Sell
19,921
-3,034
-13% -$202K 0.01% 757
2013
Q2 		$1.28M Buy
+22,955
New +$1.43M 0.01% 750

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Suntrust Banks's BMRN Position: Q3 2019 in Review

Suntrust Banks reduced its BioMarin Pharmaceuticals (BMRN) stake by 25% in Q3 2019, selling an estimated $272K and leaving 10,624 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #840.

Suntrust Banks first reported a position in BMRN in Q2 2013 and has held it in 21 quarters since. The position peaked at $1.44M in Q3 2013. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Suntrust Banks held 10,624 shares of BioMarin Pharmaceuticals worth $716K as of Q3 2019.
  • Suntrust Banks sold 3,527 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $272K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Suntrust Banks's portfolio in Q3 2019, its #840 holding.
  • Suntrust Banks first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 21 quarters since.
  • Suntrust Banks's BioMarin Pharmaceuticals position peaked at $1.44M in Q3 2013.
  • 437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Suntrust Banks's 13F filing for Q3 2019, filed 12 Nov 2019.